Clinical Trial

Point-of-Care Testing (POCT) for Guided Precision Anticoagulation With Warfarin: A Multicenter, Non-concurrent Controlled Study

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated October 16, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to compare the key clinical indicators such as the time to achieve INR target, frequency of dose adjustment, and the incidence of thrombotic and hemorrhagic events between Point-of-Care Testing (POCT) and pyrosequencing technology in the precision dosing of warfarin, in order to assess whether POCT-based warfarin genetic testing is beneficial for improving the quality of anticoagulation treatment for patients.
Trial Details
NCT Number NCT06645275
Lead Sponsor RenJi Hospital
Conditions Anticoagulation
Enrollment 416 participants
Start Date 2025-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-16